Dianthus Therapeutics (DNTH) Operating Leases (2022 - 2025)

Dianthus Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• In Q4 2025, Operating Leases fell 12.98% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 12.98% YoY), while the FY2025 annual figure was $1.0 million, down 12.98% from the prior year.
• Operating Leases was $1.0 million for Q4 2025 at Dianthus Therapeutics, down from $1.1 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $32.4 million in Q1 2022 to a low of $30000.0 in Q2 2024.
• Historically, Operating Leases has averaged $7.5 million across 4 years, with a median of $1.1 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Operating Leases sank 99.05% in 2023, then jumped 3630.0% in 2025.
• A 4-year view of Operating Leases shows it stood at $438000.0 in 2022, then sank by 61.64% to $168000.0 in 2023, then surged by 597.02% to $1.2 million in 2024, then fell by 12.98% to $1.0 million in 2025.
• The last three Operating Leases figures came in at $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.